CCM
IMRX icon

Corsair Capital Management’s Immuneering IMRX Stock Holding History

Corsair Capital Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,000
Closed -$22K – 131
2024
Q4 		$22K Hold
10,000
– – ﹤0.01% 116
2024
Q3 		$24.9K Buy
+10,000
New +$14.5K 0.01% 115

Other funds holding IMRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SM
Southport Management Wilson, Wyoming $28.6M AUM 41.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Corsair Capital Management's IMRX Position: Q1 2025 in Review

Corsair Capital Management sold out of Immuneering (IMRX) in Q1 2025, closing a stake of 10,000 shares — an estimated $22K sold.

Corsair Capital Management first reported a position in IMRX in Q3 2024 and held it in 2 quarters. The position peaked at $24.9K in Q3 2024. 35 funds tracked by Wall St. Rank hold IMRX as of Q1 2025.

  • Corsair Capital Management reported no remaining Immuneering position as of Q1 2025 after selling out during the quarter.
  • Corsair Capital Management sold 10,000 Immuneering shares in Q1 2025, an estimated $22K.
  • Corsair Capital Management first reported a position in Immuneering in Q3 2024 and held it in 2 quarters.
  • Corsair Capital Management's Immuneering position peaked at $24.9K in Q3 2024.
  • 35 funds tracked by Wall St. Rank held Immuneering as of Q1 2025.

Based on Corsair Capital Management's 13F filing for Q1 2025, filed 15 May 2025.